Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HOVON 178 WM epcoritamab in relapsed or refractory Waldenstrom's macroglobulinemia
NL-OMON58855Phase 2Recruiting
- Sponsor
- HOVON
- Start
- Jun 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of epcoritamab in Waldenström macroglobulinemia (WM), sponsored by HOVON. Started Jun 2026; status: recruiting.
02
Drugs
epcoritamab
03
Conditions
Waldenström macroglobulinemia (WM)
Beyond the preview
Go deeper on NL-OMON58855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58855.